Sourasky Medical Center (Ichilov)
Pourquoi choisir Israël pour la thérapie par cellules souches de cordon ombilical ?
Accédez à des solutions avancées de thérapie par cellules souches de cordon ombilical dans des cliniques de confiance .
| Israël | Turquie | Espagne | |
| Traitement du sang de cordon ombilical | de $14,500 | de $5,000 | de $7,500 |
Bookimed ne facture pas de frais supplémentaires pour les prix des Traitement du sang de cordon ombilical. Les tarifs sont issus des listes de prix officielles des cliniques. Vous payez directement à la clinique lors de votre arrivée pour votre Traitement du sang de cordon ombilical.
Bookimed s'engage pour votre sécurité. Nous ne travaillons qu'avec des établissements médicaux qui respectent des normes internationales élevées dans Traitement du sang de cordon ombilical et qui possèdent les licences nécessaires pour accueillir des patients internationaux dans le monde entier.
Bookimed offre une assistance experte gratuite. Un coordinateur médical personnel vous accompagne avant, pendant et après votre traitement, en résolvant tous les problèmes. Vous n'êtes jamais seul dans votre parcours de Traitement du sang de cordon ombilical.
Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.
She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.
She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.
She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.
Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.
He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.
He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.